Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: 10.1038/leu.2016.20
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2016
- Urheber
-
Miranda, M. B.
Lauseker, M.
Kraus, M.-P.
Proetel, U.
Hanfstein, B.
Fabarius, A.
Baerlocher, G. M.
Heim, D.
Hossfeld, D. K.
Kolb, H.-J.
Krause, S. W.
Nerl, C.
Brümmendorf, Tim Henrik
Verbeek, W.
Fauser, A. A.
Prümmer, O.
Neben, K.
Hess, U.
Mahlberg, R.
Plöger, C.
Flasshove, M.
Rendenbach, B.
Hofmann, W.-K.
Müller, M. C.
Pfirrmann, M.
Hochhaus, A.
Hasford, J.
Hehlmann, R.
Saußele, Susanne
- DOI
-
10.18154/RWTH-CONV-211206
- URN
-
urn:nbn:de:101:1-2018101106082973282994
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miranda, M. B.
- Lauseker, M.
- Kraus, M.-P.
- Proetel, U.
- Hanfstein, B.
- Fabarius, A.
- Baerlocher, G. M.
- Heim, D.
- Hossfeld, D. K.
- Kolb, H.-J.
- Krause, S. W.
- Nerl, C.
- Brümmendorf, Tim Henrik
- Verbeek, W.
- Fauser, A. A.
- Prümmer, O.
- Neben, K.
- Hess, U.
- Mahlberg, R.
- Plöger, C.
- Flasshove, M.
- Rendenbach, B.
- Hofmann, W.-K.
- Müller, M. C.
- Pfirrmann, M.
- Hochhaus, A.
- Hasford, J.
- Hehlmann, R.
- Saußele, Susanne
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2016
Ähnliche Objekte (12)
Imatinib Mesylate in Chronic Myeloid Leukemia
Chromothripsis in myeloid malignancies
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Charakterisierung der Wirkungen von Imatinib mesilat und Cytarabin auf Philadelphiachromosom-positive CML-Zellen
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Myeloid malignancies: mutations, models and management
ASXL1/2 mutations and myeloid malignancies
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Imatinib Mesylate in Chronic Myeloid Leukemia
Chromothripsis in myeloid malignancies
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Charakterisierung der Wirkungen von Imatinib mesilat und Cytarabin auf Philadelphiachromosom-positive CML-Zellen
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Myeloid malignancies: mutations, models and management
ASXL1/2 mutations and myeloid malignancies
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Imatinib Mesylate in Chronic Myeloid Leukemia
Chromothripsis in myeloid malignancies
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Charakterisierung der Wirkungen von Imatinib mesilat und Cytarabin auf Philadelphiachromosom-positive CML-Zellen
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Myeloid malignancies: mutations, models and management
ASXL1/2 mutations and myeloid malignancies